Image source: Shutterstock

Highlights

  • 4DMedical renewed its contract with Cleveland Clinic for three years, valued at AUD 227,000.
  • The company saw a 265% YoY increase in revenue, reaching AUD 2.90 million in 1HFY25.
  • 301 sites now use 4DX’s SaaS technology, reflecting a 41% increase YoY.
  • The company delivered over 8,000 scans, a 37% increase from 2HFY24 and 77% YoY growth.
  • 4DX reported a loss of AUD 19.17 million, higher than AUD 15.61 million in 1HFY24.

4DMedical Limited (ASX:4DX) is an ASX-listed medical technology company with specialisation in lung function assessment. Recently, 4DMedical renewed and extended its contract with Cleveland Clinic, a globally recognised academic medical centre. The contract has been renewed for three-years and is valued at a minimum of AUD 227,000. It builds on an existing multi-year collaboration for pulmonary function analysis using 4DX’s SaaS technology.

Recent Half-Year Performance

For the half-year ended 31 December 2024 (1HFY25), 4DMedical recorded a 265% YoY increase in operating revenue, reaching AUD 2.90 million, compared to AUD 0.79 million in the previous corresponding period (pcp). The company's global footprint expanded in 1HFY25, with 301 sites now utilising its SaaS product, marking a 41% increase from pcp and 24% growth from the previous half-year (2HFY24).

Despite the  revenue growth, the company reported a loss of AUD 19.17 million, higher than the AUD 15.61 million loss in 1HFY24.

During the reported period, the company delivered over 8,000 scans, representing a 37% increase from 2HFY24 and 77% growth compared to pcp.

Outlook

The company is progressing with FDA submissions, including clearance for CT:VQ™, which is expected to unlock new revenue opportunities. Notably, the company recently secured FDA clearance for IQ-UIP™.

Furthermore, the reseller agreement with Philips is already in its implementation phase, positioning 4DMedical for increased sales and market expansion.

Share performance of 4DX

4DX shares closed 2.70% higher at AUD 0.38 per share on 19 March 2025. Over the past year, 4DX’s share price has dropped by almost 43.70% and in the last three months, it has declined by 15.56%.

52-week high of 4DX is AUD 0.755, recorded on 18 March 2024 and 52-week low is AUD 0.355, recorded on 13 March 2025.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 19 March 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.